alexa Efficacy and Safety of Oncoxin-Viusid, a Nutritional Supplement, in Twenty Patients with Stage IIB-III of Cutaneous Melanoma: An open-Label Proof of Concept Study| Abstract
ISSN: 1948-5956

Journal of Cancer Science & Therapy
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
  • Research Article   
  • J Cancer Sci Ther/Vol.11.9 263(2019),

Efficacy and Safety of Oncoxin-Viusid, a Nutritional Supplement, in Twenty Patients with Stage IIB-III of Cutaneous Melanoma: An open-Label Proof of Concept Study

Olaine R. Gray Lovio1*, Alfredo Abreu Daniel2, Liset A. García Yánez2, Marta Osorio Rodríguez3, Carlos Vásquez González3, Juan J. Lence Anta4 and Eduardo Sanz5
1Department of Dermatology and Infectious Diseases, Manuel Fajardo University Hospital, La Habana, Cuba
2Department of Dermatology, Manuel Fajardo University Hospital, La Habana, Cuba
3Department of Oncology, National Institute of Oncology (INOR), La Habana, Cuba
4Department of Biostatistics, National Institute of Oncology (INOR), La Habana, Cuba
5Scientific Department, Catalysis Unit, S.L., Madrid, Spain
*Corresponding Author : Olaine R. Gray Lovio, Specialist in Dermatology, Master of Infectious Diseases, Department of Dermatology and Infectious Diseases, Manuel Fajardo University Hospital, La Habana, Cuba, Tel: +5378382593, Email: [email protected]

Received Date: Aug 12, 2019 / Accepted Date: Sep 10, 2019 / Published Date: Sep 17, 2019

Abstract

Objective: Surgery is the treatment of choice of melanoma, but in advanced stages, it is often necessary to combine this with other therapeutic options. Oncoxin-Viusid has demonstrated antitumor and immunomodulating effects in various type of cancers, in addition to boosting the antiproliferative effect of standard chemotherapy agents in experimental studies. Our study was aimed to identify the efficacy and safety of the Oncoxin-Viusid as an adjuvant treatment for patients with stage IIB-III cutaneous melanomas.

Methods: From September 2014 to June 2017, a proof of concept, open label nonrandomized and uncontrolled study was conducted at the Manuel Fajardo University Hospital (Havana, Cuba), including 20 patients with histologically confirmed diagnosis of stage IIB-III of primary cutaneous melanoma. All patients received surgical treatment with or without chemotherapy in combination with Oncoxin-Viusid 25 ml twice a day for 1 year. Progression-free survival rate with its 95% confidence interval was estimated after one year of inclusion and quality of life was measured at inclusion and after a year using QLQ-C-30 EORTC questionnaire.

Results: Most of the patients were women with a median age of 59 years, cutaneous phototypes II-III, occupations without photo exposure, without personal history of skin cancer or family of cutaneous melanoma. 40% of patients presented with superficial spreading melanoma, epithelioid presentation being histologically predominant. Adverse reactions were, for the most part, mild and short-lived. Only 2 patients progressed and one of them died. Two patients were early withdrawal to follow-up. The progression-free survival rate was 90% (95% CI: 0.65-0.97).

Conclusion: Nutritional supplement Oncoxin-Viusid showed safety; meanwhile patients kept a stable quality of life at the end of study and a high progression-free survival rate.

Keywords: Cutaneous melanoma; Nutritional supplement; Oncoxin- Viusid; Proof of concept; Quality of life

Citation: Gray Lovio OR, Daniel AA, García Yánez LA, Rodríguez MO, González CV, et al. (2019) Efficacy and Safety of Oncoxin-Viusid, a Nutritional Supplement, in Twenty Patients with Stage IIB-III of Cutaneous Melanoma: An open-Label Proof of Concept Study. J Cancer Sci Ther 11: 260-265.

Copyright: © 2019 Gray Lovio OR, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Select your language of interest to view the total content in your interested language

Post Your Comment Citation
Share This Article
Relevant Topics
Article Usage
  • Total views: 109
  • [From(publication date): 0-0 - Nov 14, 2019]
  • Breakdown by view type
  • HTML page views: 86
  • PDF downloads: 23
Top